WO2000007463A1 - Complements de multivitamines et mineraux, destines aux femmes - Google Patents

Complements de multivitamines et mineraux, destines aux femmes Download PDF

Info

Publication number
WO2000007463A1
WO2000007463A1 PCT/US1999/017541 US9917541W WO0007463A1 WO 2000007463 A1 WO2000007463 A1 WO 2000007463A1 US 9917541 W US9917541 W US 9917541W WO 0007463 A1 WO0007463 A1 WO 0007463A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
total daily
daily dosage
pharmaceutically acceptable
compound
Prior art date
Application number
PCT/US1999/017541
Other languages
English (en)
Inventor
George N. Paradissis
R. Saul Levinson
Robert C. Cuca
Patrick Paul Vanek
Original Assignee
Kv Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kv Pharmaceutical Company filed Critical Kv Pharmaceutical Company
Priority to AU52522/99A priority Critical patent/AU5252299A/en
Publication of WO2000007463A1 publication Critical patent/WO2000007463A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to multi -vitamin and mineral supplements, and particularly to multi -vitamin and mineral supplements for administration to women.
  • the supplements are specifically tailored to meet nutritional requirements and maintain a woman's health during specific stages of life.
  • the present invention also relates to methods of optimizing the health of women by providing multi-vitamin and mineral supplements which are specifically tailored to achieve optimal regulation of growth, maintenance and repair of body tissue during specific stages of life with minimal side effects. Methods of formulating multi -vitamin and mineral supplements for life stages are also encompassed by the present invention.
  • Vitamin and mineral preparations are commonly administered to treat specific medical conditions or as general nutritional supplements. Recent studies have elucidated the important physiological roles played by vitamins and minerals, and established a correlation between deficiencies or excesses of these nutrients and the etiologies of certain disease states in humans. See, e.g., Diplock, "Antioxidant Nutrients and Disease Prevention: An Overview," Am. J. Clin. Nutr., 53:189-193 (1991) ; Document Geigy Scientific Tables, 457-497 (Diem and Cembuer eds . , 7th ea., 1975) .
  • U.S. Patent No. 4,994,283 discloses nutritional mineral supplements which include iron and calcium compounds in combination with citrates or tartrates, ascorbates, and fructose.
  • the tendency of calcium to inhibit the bioavailability of iron is said to be reduced in such compositions, so that the conjoint bioavailability of these two minerals is enhanced.
  • U.S. Patent No. 4,431,634 maximizes bioavailability of iron in prenatal iron supplements by maintaining the amount of calcium compounds in the supplement at 300 mg or less and the amount of magnesium compounds at 75 mg or less per dosage unit.
  • a multi-vitamin and mineral dietary supplement which includes (a) one or more divalent dietary mineral components such as calcium or magnesium; and (b) a bioavailable iron component, presenting a controlled release form and adapted to be released in a controlled manner in the gastrointestinal tract.
  • U.S. Patent No. 4,710,387 discloses a nutritional supplement preparation for pregnant and breast-feeding women which contains 10-20% by weight of protein, 16-28% by weight of fat, 43-65% by weight carbohydrates, and at most 3.5% by weight of moisture, minerals, trace elements and vitamins .
  • Multi -vitamin and mineral formulations which are directed specifically to woman have been disclosed in prior patents and in the medical literature.
  • the Physicians' Desk Reference (PDR) for Nonprescription Drugs, 9th Edition, 718-19 (1988) discloses a complete calcium/vitamin/mineral supplement program formulated for women.
  • the program contains two specific formulas. One formulation is directed to woman between the ages of 14 and 40, and the other fomulation is directed to woman over the age of 40. These formulations do not specifically distinguish between the varying physiological states experienced by women throughout the course of their lives. In fact, by providing one formulation for the broad category of woman aged 14-40, this disclosure highlights the need for more specific formulations.
  • WO 95/35098 discloses multi-vitamin and mineral supplements for administration to lactating, non- lactating, and menopausal women which comprise specific regimens of critical nutritional agents.
  • This reference teaches formulations containing high amounts of iron, zinc and vitamin B 1# and low amounts of vitamin B 12 and vitamin B 6 .
  • conventional prenatal supplements are not ideally suited for women during other phases of their lives.
  • the foregoing efforts to improve vitamin and mineral supplementation for women in general, have lacked the specificity required for achieving formulations which are truly adapted to meet the physiological needs of woman at various times in their lives.
  • the nutritional needs of lactating women following a pregnancy differ from the nutritional needs of women during pregnancy.
  • the vitamin and mineral requirements for non-lactating and menopausal women also differ from the requirements of pregnant women.
  • the present invention overcomes the shortcomings of known nutritional supplements by providing multivitamin and mineral supplements which are specifically tailored for administration to woman during various stages of life, and more specifically to lactating, nonlactating, and menopausal women.
  • the formulations of the invention have been found to maximize the benefits of vitamin and mineral supplementation for women by specifically formulating the products to meet the physiological requirements of women during these life stages.
  • compositions of the invention include certain essential nutritional components in dosage levels which have been found to optimize the maintenance of a woman's health during each of the noted stages of life.
  • Minerals such as calcium, zinc and iron are dosed (i.e. provided in the supplement) in the form of a corresponding pharmaceutically acceptable compound.
  • a multi -vitamin and mineral supplement for administration to a lactating woman is provided.
  • This supplement is specially designed to aid in fulfilling the dietary needs of women who are producing and secreting milk, that is, lactating women.
  • the multi-vitamin and mineral supplement comprises:
  • a multi -vitamin and mineral supplement for administration to a non-lactating woman is also provided by the invention.
  • This supplement is designed to aid in fulfilling the dietary needs of women during the period after puberty and before menopause who are neither pregnant nor lactating.
  • This formulation comprises:
  • (k) a total daily dosage of about 12 mg to about 30 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
  • a multi -vitamin and mineral supplement for administration to a menopausal woman is also provided.
  • menopausal women may be asymptomatic or experience a variety of symptoms including hot flushes. See The Merck Manual of Diagnosis and Therapy 15th edition, 1713-1715. Most menopausal women experience hot flushes for over a year and 25 to 50% experience hot flushes for more than five years.
  • the supplement for menopausal women of the present invention comprises:
  • a method for optimizing the health of a woman is also included m the present invention.
  • the method comprises administering to said woman a multi-vitamin and mineral supplement comprising vitamins and minerals m amounts adjusted according to varying physiological conditions of said woman over a lifetime.
  • a method for formulating a multi -vitamin and mineral supplement which optimizes the health of a woman is also included. This method comprises:
  • step (d) preparing a multi-vitamm and mineral supplement containing the determined optimal amounts of each vitamin and mineral of step (c) .
  • the invention provides the above-described multi -vitamin and mineral supplements for administration to lactating, non-lactatmg, and menopausal women, as well as methods both for optimizing the health of women and for preparing formulations for same.
  • the formulations of the invention comprise specific regimens of critical nutritional agents, m order to better meet the physiological requirements of women and maintain good health throughout life.
  • Nutrient refers to any substance in a human or other living organism which regulates the growth, maintenance, and repair of body tissue, as well as any substance which provides energy or structural material to the body .
  • Essential nutrient refers to any nutrient which is not produced by a human or other living organism and thus must be obtained from an external source .
  • Body tissue refers to any substance in a human or other living organism which is composed of the cells of said human or other organism, respectively.
  • Total daily dosage refers to the amount of any nutrient formulated for administration during any 24 hour period of time.
  • AM dose refers to any dose of a multi -vitamin and mineral supplement formulated for administration in the morning hours
  • PM dose refers to any dose of a multi-vitamin and mineral supplement formulated for administration in the afternoon, evening or nighttime hours
  • Life stage refers to a specific period of time during the course of an individual's life.
  • the invention provides multi -vitamin and mineral supplements which are tailored for women at different life stages, and specifically for administration to lactating, non-lactating, and menopausal women.
  • the formulations of the invention include certain essential nutritional components in dosage levels which have been found to optimize the maintenance of a woman's health during each of these stages of life.
  • a multi -vitamin and mineral supplement for administration to a lactating woman which comprises: (a) from about 320 mg to ' about 480 mg of elemental calcium dosed in the form of a pharmaceutically acceptable calcium compound;
  • a particularly preferred multi -vitamin and mineral supplement for lactating women also includes from about
  • a multi -vitamin and mineral supplement for administration to a non-lactating woman is also provided by the invention.
  • This supplement is designed to specifically aid in fulfilling the dietary needs of women during the period after puberty and before menopause who are neither pregnant nor lactating.
  • the invention may be used by a non-lactating woman ' has never given birth or a non-lactating woman has given birth one or more times.
  • the formulation comprises:
  • the multi -vitamin and mineral supplement for non-lactating women also includes from about 160 mg to about 240 mg of a pharmaceutically acceptable magnesium compound and about 95 mg to about 300 mg of vitamin C, or more preferably from about 180 mg to about 220 mg of a pharmaceutically acceptable magnesium compound and from about 180 to about 220 mg of vitamin C, from about 0.040 mg to about 0.060 mg of a pharmaceutically acceptable molybdenum compound, and from about 0.080 mg to about 0.120 mg of a pharmaceutically acceptable chromium compound.
  • the present invention includes a multi -vitamin and mineral supplement for administration to a non-lactating woman which comprises:
  • (k) a total daily dosage of about 14 mg to about 25 mg of elemental zinc dosed in the form of a pharmaceutically acceptable zinc compound.
  • the present invention includes a multi -vitamin and mineral supplement for administration to a non-lactating woman which comprises:
  • a multi -vitamin and mineral supplement for administration to a menopausal woman which comprises:
  • a particularly preferred multi-vitamin and mineral supplement for menopausal women also includes about 160 mg to about 240 mg of a pharmaceutically acceptable magnesium compound.
  • a method for optimizing the health of a woman comprises administering to said woman a multi -vitamin and mineral supplement comprising vitamins and minerals in amounts adjusted according to varying physiological conditions of said woman over a lifetime.
  • the method comprises administering to said non-lactating woman a multi -vitamin and mineral supplement comprising:
  • a method for formulating a multi -vitamin and mineral supplement which optimizes the health of a woman is also included. This method comprises:
  • step (c) determining optimal amounts of each vitamin and mineral according to varying physiological conditions of said woman over a lifetime; and (d) preparing a multi -vitamin and mineral supplement containing the determined optimal amounts of each vitamin and mineral of step (c) .
  • the formulations vary in the critical nutritional agents included and amounts thereof.
  • levels of calcium are higher for administration to lactating women than in the non-lactating and menopausal formulations.
  • the amount of iron in the menopausal formulation is reduced greatly in comparison to the formulations for lactating and non-lactating women.
  • Molybdenum and chromium are added to the menopausal formulation because these agents are believed to assist the immune system, which is a useful therapy in older women.
  • the present invention addresses the problem of providing optimal supplementation of vitamins and minerals while eliminating or at least minimizing said side effects. Accordingly, the present invention is designed to minimize adverse effects often experienced by women when taking vitamin and mineral supplements while providing the optimal amount of vitamins and minerals.
  • the present invention is contemplated for use by women of varying physical conditions, without limitation, including normal, healthy women and women with a physical disorder, vitamin or mineral deficiency, or a nutritional disorder.
  • Non-limiting exemplary vitamin deficiencies include vitamin A deficiency, hypervitaminosis A, vitamin D deficiency and dependancy, hypervitaminosis D, vitamin E deficiency and toxicity, vitamin K deficiency, hypervitaminosis K, essential fatty acid deficiency, thiamine deficiency, riboflavin deficiency, niacin deficiency, vitamin B 6 deficiency and dependency, biotin deficiency and dependancy, pantothenic acid deficiency, carnitine deficiency and vitamin C deficiency.
  • Non- limiting exemplary mineral deficiencies include phosphate depletion, iodine deficiency, fluorine deficiency, zinc deficiency, disturbances in copper metabolism, acquired copper deficiency, acquired copper toxicosis, inherited copper deficiency and inherited copper toxicosis.
  • Useful pharmaceutically acceptable calcium compounds include, without limitation, any of the well-known calcium supplements such as calcium carbonate, calcium phosphate, calcium citrate, calcium sulfate, calcium oxide, calcium hydroxide, calcium apatite, calcium citrate-maleate, calcium lactate, calcium levulinate and the like.
  • calcium compounds selected from the group consisting of calcium carbonate, calcium sulfate, and mixtures thereof are employed.
  • Useful pharmaceutically acceptable zinc compounds include, without limitation, zinc sulfate, zinc chloride, and zinc oxide, with zinc sulfate being preferred.
  • the pharmaceutically acceptable iron compound may be chosen from any of the well-known iron II (ferrous) or iron III (ferric) supplements, such as ferrous fumarate, ferrous sulfate, carbonyl iron, ferrous glucomate, ferrous chloride, ferrous lactate, ferrous tartrate, ferrous succinate, ferrous glutamate, ferrous citrate, ferrous pyrophosphate, ferrous cholinisocitrate, ferrous carbonate, iron-sugarcarboxylate complexes and the like, without limitation.
  • iron II ferrous
  • iron III iron supplements
  • the iron compound comprises a pharmaceutically acceptable iron compound contained in a pharmaceutically acceptable film forming material which permits release of the iron in the stomach of a woman administered the supplement.
  • the iron may or may not be coated.
  • Suitable coatings include, without limitation, any material known in the art for forming enteric, controlled release, or sustained release coatings, such as cellulose ethers including hydroxypropyl methylcellulose, methylcellulose, ethylcellulose, and carboxymethylcellulose; cellulose esters such as cellulose acetate, cellulose acetate phthalate, and cellulose nitrate; acrylate and methacrylate copolymers; and the like.
  • the coated iron compound has been found to provide increased iron bioavailability by minimizing interaction between the iron compound and divalent cations such as calcium in the nutritional supplement. Release of the iron in the intestine also minimizes stomach upset. More preferably, the iron is in the coating and is released in the stomach. It is also possible in the present formulations to combine various forms of extended release particles or coatings along with immediate release particles or coatings to deliver the various vitamins and mineral supplements over various rates of release, without limitation.
  • certain agents such as thiamine, niacinamide, pyridoxine, ascorbic acid, folic acid, iron and riboflavin could be released over an extended period of time from two hours up to 24 hours while other agents such as beta-carotene, vitamin A, vitamin D 3 , vitamin B 12 , biotin, pantothenic acid, copper, zinc, magnesium, potassium, iodine, chromium, molybdenum and selenium can be administered as immediate release.
  • beta-carotene vitamin A, vitamin D 3 , vitamin B 12 , biotin, pantothenic acid, copper, zinc, magnesium, potassium, iodine, chromium, molybdenum and selenium
  • the ability to obtain extended and immediate release characteristics is performed using well known procedures and techniques available to the ordinary skilled artisan.
  • the multi -vitamin and mineral supplements of the invention may include additional nutritional components well-known in the art.
  • the supplements may include elemental magnesium dosed in the form of one or more pharmaceutically acceptable magnesium compounds, without limitation, such as magnesium stearate, magnesium carbonate, magnesium oxide, magnesium hydroxide, and magnesium sulfate.
  • Magnesium stearate is a preferred form of the compound.
  • the formulations may also include vitamin C, from about 0.1 mg to about 1 mg of folic acid, from 1 mg to about 3 mg of copper, and from about 0.05 mg to about 0.25 mg of iodine.
  • Other nutritional agents well-known in the art may be included as desired.
  • the optional vitamin C and folic acid nutritional components are coated to provide controlled release of these agents.
  • the techniques and materials discussed above that are utilized to coat iron are preferred.
  • compositions include, without limitation, cupric oxide, cupric sulfate, or cupric gluconate, with cupric oxide being preferred.
  • Preferred pharmaceutically acceptable iodine compounds include sodium or potassium iodide, with potassium iodide being most preferred.
  • the vitamins in the formulation may be provided in any source, without limitation.
  • the amounts shown for each vitamin and mineral indicate the actual vitamin and mineral amounts, in milligrams (mg) , in the formulations regardless of source, except where otherwise indicated.
  • Vitamin A may be provided in any source, such as a preformed vitamin A compound or a vitamin A precursor, or any combination thereof.
  • the amount of vitamin A in the formulations is expressed as an International Unit (I.U.) which is a measure of vitamin activity. Therefore, the indicated amounts for vitamin A refer to any amount of any precursor or preformed vitamin A compound, from any source whatsoever, which would result in the indicated amount of vitamin A activity in the body.
  • I.U. International Unit
  • the nutritional supplements of the invention may be provided in any suitable dosage form known in the art, without limitation.
  • the compositions may be incorporated into tablets, powders, granules, beads, chewable lozenges, capsules, liquids, or similar conventional dosage forms, using conventional equipment and techniques known in the art. Tablet dosage forms are preferred.
  • the dosage form can be in the form of a bi-layer tablet composed of at least one extended-release layer and at least one immediaterelease layer.
  • the bi-layer tablet can be coated for ease of administration or can be enteric coated to reduce any gastric irritation and the unpleasant "burping" produced by the vitamins and minerals.
  • multi-particulate design of extended release and immediate-release components can be enteric coated and compressed into a tablet or filled into hard or soft gelatin capsules.
  • the nutritional components are normally blended with conventional excipients such as binders, including gelatin, pregelatinized starch, and the like; lubricants, such as hydrogenated vegetable oil, stearic acid, and the like; diluents, such as lactose, mannose, and sucrose; disintegrants, such as carboxymethyl cellulose and sodium starch glycolate; suspending agents, such as povidone, polyvinyl alcohol and the like; absorbent, such as silicon dioxide; preservatives, such as methylparaben, propylparaben, and sodium benzoate; surfactants, such as sodium lauryl sulfate, polysorbate 80, and the like; and colorants, such as F.D. & C dyes and lakes.
  • binders including gelatin, pregelatinized starch, and the like
  • lubricants such as hydrogenated vegetable oil, stearic acid, and the like
  • diluents such as lactose, mannose, and sucrose
  • inert, pharmaceutically acceptable carriers can be used which are either solid or liquid.
  • Solid form preparations include powders, tablets, dispersible granules, capsules, and cachets.
  • a solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers , lubricants, suspending agents, binders or tablet disintegrating agents; it can also be encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active compounds.
  • the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from 5 or 10 to about 90 percent of the active ingredient.
  • Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, coca butter, and the like.
  • the term "preparation” is intended to include the formulation of the active compounds with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it.
  • cachets are included. Tablets, powders, cachets, and capsules can be used a solid dosage forms suitable for oral administration.
  • Liquid form preparations include solutions, suspensions, and emulsions.
  • water or water/propylene glycol solutions for parenteral injection may be used.
  • Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
  • solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • solid form preparations are most conveniently provided in unit dose form and as such are used to provide a single liquid dosage unit. Alternately, sufficient solid may be provided so that after conversion to liquid form, multiple individual liquid doses may be obtained by measuring predetermined volumes of the liquid form preparation as with a syringe, teaspoon, or other volumetric container. When multiple liquid doses are so prepared, it is preferred to maintain the unused portion of said liquid doses at low temperature (i.e., under refrigeration) in order to retard possible decomposition.
  • the solid and liquid forms may contain, in addition to the active addition to the material, flavorants, colorants, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents , and the like.
  • the liquid utilized for preparing the liquid form preparation may be water, isotonic water, ethanol , glycerine, propylene glycol, and the like as well as mixtures thereof. Naturally, the liquid utilized will be chosen with regard to the route of administration, for example, liquid preparations containing large amounts of ethanol are not suitable for parenteral use.
  • the preparations are m unit dosage form.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active components.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself or it can be the appropriate number of any of these m packaged form.
  • the quantity of active compound m a unit dose of preparation may be varied according to the particular application and the potency of the active ingredients.
  • the total daily dosage may be divided and administered m portions during the day if desired or at one time, morning, afternoon, or night as well as biphasic, triphasic, etc.
  • the portion administed in one dose during a day need not be equal to all or any other doses administered during a day.
  • the total daily dosage is divided into two different doses, such as an AM and a PM dose, then one vitamin, such as vitamin B 6 , may present m a lesser amount in the AM dose than m the PM dose .
  • vitamins and/or minerals may be treated m such a manner.
  • the amount of a vitamin and mineral m each dose is determined as the amount which will achieve optimal or maximal efficacy with minimal side effects.
  • the use of such unequal doses during the course of a day may apply to the entire formulation, or any individual vitamin or mineral in said formulation.
  • Controlled and uncontrolled release formulations as well as sustained release, extended release, timed release, delayed release and ' other such formulations, without limitation, are contemplated for use with the present invention.
  • the products of the invention are preferably intended for administration to humans, it will be understood that the formulation may also be utilized in veterinary therapies for other animals.
  • I.U represents International Units.
  • Multi-Vitamin and Mineral Supplements The following compositions were used to prepare multi -vitamin and mineral supplements for administration to lactating, non-lactating, and menopausal women:
  • Example 2 Tablets incorporating the above formulations were prepared using conventional methods and materials known m the pharmaceutical art. The resulting nutritional supplement tablets were recovered and stored for future use .
  • Example 2
  • compositions were used to prepare multi -vitamin and mineral supplements for administration to lactating, non-lactating and menopausal women.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ces compléments de multivitamines et minéraux, destinés à être administrés à des femmes n'allaitant pas, comprennent des dosages spécifiques et sur mesure de vitamines et minéraux servant à palier les besoins physiologiques de ces femmes. L'invention concerne également des méthodes d'optimisation de la santé de femmes, consistant à leur apporter des compléments de multivitamines et minéraux conçus sur mesure pour effectuer une régulation optimale de la croissance, l'entretien et la réparation des tissus corporels, lors d'étapes spécifiques de la vie, avec un minimum d'effets secondaires. L'invention concerne également des procédés de formulation d'un complément de multivitamines et minéraux, optimisant la santé d'une femme, consistant à identifier les étapes de la vie correspondant aux besoins nutritionnels spécifiques, en fonction des conditions physiologiques changeant au cours d'une vie, et à choisir des types spécifiques et des quantités optimales de vitamines et minéraux pour ces étapes de la vie.
PCT/US1999/017541 1998-08-04 1999-08-02 Complements de multivitamines et mineraux, destines aux femmes WO2000007463A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU52522/99A AU5252299A (en) 1998-08-04 1999-08-02 Multi-vitamin and mineral supplements for women

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12846698A 1998-08-04 1998-08-04
US09/128,466 1998-08-04

Publications (1)

Publication Number Publication Date
WO2000007463A1 true WO2000007463A1 (fr) 2000-02-17

Family

ID=22435510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017541 WO2000007463A1 (fr) 1998-08-04 1999-08-02 Complements de multivitamines et mineraux, destines aux femmes

Country Status (2)

Country Link
AU (1) AU5252299A (fr)
WO (1) WO2000007463A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009020595A2 (fr) * 2007-08-03 2009-02-12 Shaklee Corporation Système de complément nutritionnel
US8057784B2 (en) 2004-03-04 2011-11-15 Quest International B.V. Particulate flavoring composition
US9763989B2 (en) 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
CN110123836A (zh) * 2019-05-20 2019-08-16 昆明朗盛生物科技有限公司 钙锌维生素d泛酸片的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005093A1 (fr) * 1993-08-14 1995-02-23 Eckes Ag Aliments liquides enrichis stables au stockage et leur procede de production
WO1995035098A1 (fr) * 1994-06-20 1995-12-28 Kv Pharmaceutical Company Complements multivitamines et mineraux pour la femme
US5514382A (en) * 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
US5589468A (en) * 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients
EP0514451B1 (fr) * 1990-02-05 1997-01-15 LifeScience Corporation Complements alimentaires comprenant des vitamines et des sels mineraux

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0514451B1 (fr) * 1990-02-05 1997-01-15 LifeScience Corporation Complements alimentaires comprenant des vitamines et des sels mineraux
WO1995005093A1 (fr) * 1993-08-14 1995-02-23 Eckes Ag Aliments liquides enrichis stables au stockage et leur procede de production
WO1995035098A1 (fr) * 1994-06-20 1995-12-28 Kv Pharmaceutical Company Complements multivitamines et mineraux pour la femme
US5514382A (en) * 1994-10-17 1996-05-07 Sultenfuss; Sherry Daily vitamin and mineral supplement for women
US5589468A (en) * 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PASSMORE R. AND M.A. EASTWOOD: "Human Nutrition and Dietetics", 1986, CHURCHILL LIVINGSTONE, EDINBURGH LONDON MELBOURNE AND NEW YORK, XP002125687 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8057784B2 (en) 2004-03-04 2011-11-15 Quest International B.V. Particulate flavoring composition
WO2009020595A2 (fr) * 2007-08-03 2009-02-12 Shaklee Corporation Système de complément nutritionnel
WO2009020595A3 (fr) * 2007-08-03 2009-04-09 Shaklee Corp Système de complément nutritionnel
US9248095B2 (en) 2007-08-03 2016-02-02 Shaklee Corporation Nutritional supplement system
US9763989B2 (en) 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
CN110123836A (zh) * 2019-05-20 2019-08-16 昆明朗盛生物科技有限公司 钙锌维生素d泛酸片的应用

Also Published As

Publication number Publication date
AU5252299A (en) 2000-02-28

Similar Documents

Publication Publication Date Title
US6488956B1 (en) Multi-vitamin and mineral supplements for women
US5869084A (en) Multi-vitamin and mineral supplements for women
US6228388B1 (en) Multi-vitamin and mineral supplement for pregnant women
US6299896B1 (en) Multi-vitamin and mineral supplement
US6361800B1 (en) Multi-vitamin and mineral supplement
US6953588B2 (en) Multi-vitamin and mineral supplement
US5364644A (en) Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders
US8007853B2 (en) Vitamin/mineral composition with DHA
US20020155163A1 (en) Integrated multi-vitamin and mineral combination
JP5349752B2 (ja) 微量栄養素サプリメント
US6818228B1 (en) Dietary supplements containing ultradense calcium citrate and carbonyl iron
JPH08208490A (ja) 改良されたカルシウム食事補助組成物
US8728535B2 (en) Nutritional supplement for use under physiologically stressful conditions
US20230027781A1 (en) Prenatal Dosage Forms, Methods of Administration and Kits Thereof
US11596166B2 (en) Compositions and methods for treating aging and/or improving human health
US8202546B2 (en) Nutritional supplement for use under physiologically stressful conditions
EP0305097B1 (fr) Supplément nutritif
WO2000007463A1 (fr) Complements de multivitamines et mineraux, destines aux femmes
Kenny et al. Clinical zinc deficiency during adequate enteral nutrition.
CN102578572A (zh) 一种矿物质及维生素营养补充剂
EP0432700A2 (fr) Emploi de composés du lithium dans le traitement de "combination skin"
US20030045510A1 (en) Estrogen-plus
CA2478278C (fr) Supplement a micronutriments
MXPA99000265A (en) Dietetic supplements containing calcium citrate and carbonil iron
Lederle I Obituary

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase